Balancing Potential Benefits and Risks of Bruton Tyrosine Kinase Inhibitor Therapies in Multiple Sclerosis During the COVID-19 Pandemic
Citation Manager Formats
Make Comment
See Comments

Abstract
Bruton tyrosine kinase inhibitors (BTKis) encompass a new class of therapeutics currently being evaluated for the treatment of multiple sclerosis (MS). Whether BTKis affect COVID-19 risk or severity or reduce vaccine efficacy are important but unanswered questions. Here, we provide an overview on BTKi mechanisms relevant to COVID-19 infection and vaccination and review preliminary data on BTKi use in patients with COVID-19. BTKis block B-cell receptor– and myeloid fragment crystallizable receptor–mediated signaling, thereby dampening B-cell activation, antibody class-switching, expansion, and cytokine production. Beyond antibodies, COVID-19 severity and vaccine efficacy appear largely linked to T-cell responses and interferon induction, processes not directly affected by BTKis. Given that B cells have clear roles in antigen presentation to T cells, however, it is possible that BTKis may indirectly interfere with beneficial or detrimental T-cell responses during COVID-19 infection or vaccination. In addition to these possible effects on generating a protective immune response, BTKis may attenuate the hyperinflammatory dysregulation often seen in severe cases of COVID-19 that evolves as a key risk factor in this disease. Currently available outcomes from BTKi-treated patients with COVID-19 are discussed. Clinical trials are currently underway to evaluate the safety and efficacy of BTKis in individuals with MS. Although limited data suggest a potential benefit of BTKis on outcomes for some COVID-19 patients, data from adequately powered, prospective and randomized clinical trials are lacking. Likewise, the specific effect of BTKis on the safety and efficacy of COVID-19 vaccines remains to be determined. Any potential unknown risks that BTKi therapy may present to the patient relative to COVID-19 infection, severity, and vaccine efficacy must be balanced with the importance of timely intervention to prevent or minimize MS progression.
Glossary
- BTK=
- Bruton tyrosine kinase;
- BTKi=
- Bruton tyrosine kinase inhibitor;
- CLL=
- chronic lymphocytic leukemia;
- DMT=
- disease-modifying therapy;
- Fc=
- fragment crystallizable;
- IFN=
- interferon;
- IL=
- interleukin;
- MS=
- multiple sclerosis;
- SARS-CoV-2=
- severe acute respiratory syndrome coronavirus 2;
- TLR=
- Toll-like receptor;
- XLA=
- X-linked agammaglobulinemia
Footnotes
Go to Neurology.org/NN for full disclosures. Funding information is provided at the end of the article.
↵* These authors contributed equally to this work.
The Article Processing Charge was funded by Genentech, Inc.
- Received May 4, 2021.
- Accepted in final form July 15, 2021.
- Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
- Article
- Abstract
- Glossary
- BTKis in the Treatment of MS
- BTK Signaling
- Effect of BTKis on Antimicrobial Host Defense in General
- COVID-19 Pathogenesis and Risk of Severe Infection
- BTKi Mechanisms of Action and COVID-19 Pathology
- Evidence of the Effect of BTKis on COVID-19 Risk
- Emerging Insights Regarding the Effect of BTKis on COVID-19 Vaccination
- Summary and Concluding Remarks
- Study Funding
- Disclosure
- Appendix Authors
- Footnotes
- References
- Figures & Data
- Info & Disclosures
Dr. Babak Hooshmand and Dr. David Smith
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Article
COVID-19 and MS disease-modifying therapiesJoseph R. Berger, Rachel Brandstadter, Amit Bar-Or et al.Neurology: Neuroimmunology & Neuroinflammation, May 15, 2020 -
Article
Impact of Disease-Modifying Treatments of Multiple Sclerosis on Anti–SARS-CoV-2 AntibodiesAn Observational StudyKévin Bigaut, Laurent Kremer, Thibaut Fabacher et al.Neurology: Neuroimmunology & Neuroinflammation, July 28, 2021 -
Editor's Corner
N2 year in reviewJosep Dalmau, Marinos C. Dalakas, Dennis L. Kolson et al.Neurology: Neuroimmunology & Neuroinflammation, December 18, 2020 -
Commentary
COVID-19 Vaccination in Patients With Multiple Sclerosis on Disease-Modifying TherapyAndrew Wolf, Enrique Alvarez et al.Neurology: Clinical Practice, April 14, 2021